



**A F Hottinger**

**Kontakt**

A F Hottinger

## Publikationen (6)

Zeitlberger A, Putora P, Hofer S, Schucht P, Migliorini D, Hottinger A, Roelcke U, Läubli H, Spina P, Bozinov O, Weller M, Neidert M, Hundsberger T. Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis. *J Neurooncol* 2022; 158:359–367.

Wirsching H, Riklin C, Felsberg J, Roth P, Jones D, Pfister S, Rushing E, Abrey L, Reifenberger G, Held L, von Deimling A, Ochsenbein A, von Moos R, Caparrotti F, Tabatabai G, Roelcke U, Hottinger A, Jörger F, Schmid A, Plasswilm L, Schrimpf D, Mancao C, Capper D, Conen K, Hundsberger T, Weller M. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. *Ann Oncol* 2018; 29:1423–1430.

Hottinger A, Bodmer A, Weber D, Schaller K, Mach N, Hundsberger T, Vargas M, Dunkel N, Squiban D, Espeli V, Ben Aissa A, Dietrich P. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. *Br J Cancer* 2018

Hundsberger T, Weller M, Plasswilm L, Brügge D, Gross M, Pica A, Hermann E, Pesce G, Conen K, Dietrich P, Migliorini D, Roth P, Roelcke U, Hottinger A, Putora P. Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes. *J Neurooncol* 2016; 126:175–183.

Hundsberger T, Hottinger A. Behandlungsoptionen von Hirnmetastasen – Neue Optionen durch orale und molekulare Therapeutika. *info@onkologie* 2015; 5:5–7.

Hottinger A, Bodmer A, Weber D, Schaller K, Mach N, Hundsberger T, Vargas M, Dunkel N, Squiban D, Espeli V, Aissa A, Dietrich P. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. *Br J Cancer* 2014; 110:2655–2661.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)